ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Granulocyte Colony-stimulating Factor Market Research Report 2025
Published Date: 2025-09-08
|
Report Code: QYRE-Auto-39J9441
Home | Market Reports | Health| Nursing
Global Human Granulocyte Colony stimulating Factor Market Insights and Forecast to 2028
BUY CHAPTERS

Global Human Granulocyte Colony-stimulating Factor Market Research Report 2025

Code: QYRE-Auto-39J9441
Report
2025-09-08
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Chugai Pharmaceutical
Kyowa Hakko Kirin
Sanway
GenSci
SL PHARM
Kexing Bioproducts
Qilu Pharmaceutical
CSPC
Wuzhong Pharmaceutical
Quangang Pharmaceutical
Huabei Pharmaceutical
Harbin Pharmaceutical
Amoytop Biotech
Jiuyuan Gene Engineering
Four Rings Biopharmaceutical

Human Granulocyte Colony-stimulating Factor Market

The global market for Human Granulocyte Colony-stimulating Factor was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Human Granulocyte Colony-stimulating Factor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Human Granulocyte Colony-stimulating Factor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Human Granulocyte Colony-stimulating Factor include Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, SL PHARM, Kexing Bioproducts, Qilu Pharmaceutical, CSPC, Wuzhong Pharmaceutical, Quangang Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human Granulocyte Colony-stimulating Factor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Granulocyte Colony-stimulating Factor.
The Human Granulocyte Colony-stimulating Factor market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Granulocyte Colony-stimulating Factor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Granulocyte Colony-stimulating Factor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Human Granulocyte Colony-stimulating Factor Market Report

Report Metric Details
Report Name Human Granulocyte Colony-stimulating Factor Market
Segment by Type
  • 300μg/Dose
  • 150μg/Dose
  • 75μg/Dose
  • Others
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, SL PHARM, Kexing Bioproducts, Qilu Pharmaceutical, CSPC, Wuzhong Pharmaceutical, Quangang Pharmaceutical, Huabei Pharmaceutical, Harbin Pharmaceutical, Amoytop Biotech, Jiuyuan Gene Engineering, Four Rings Biopharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Human Granulocyte Colony-stimulating Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Human Granulocyte Colony-stimulating Factor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Human Granulocyte Colony-stimulating Factor Market report?

Ans: The main players in the Human Granulocyte Colony-stimulating Factor Market are Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, SL PHARM, Kexing Bioproducts, Qilu Pharmaceutical, CSPC, Wuzhong Pharmaceutical, Quangang Pharmaceutical, Huabei Pharmaceutical, Harbin Pharmaceutical, Amoytop Biotech, Jiuyuan Gene Engineering, Four Rings Biopharmaceutical

What are the Application segmentation covered in the Human Granulocyte Colony-stimulating Factor Market report?

Ans: The Applications covered in the Human Granulocyte Colony-stimulating Factor Market report are Hospital, Clinic

What are the Type segmentation covered in the Human Granulocyte Colony-stimulating Factor Market report?

Ans: The Types covered in the Human Granulocyte Colony-stimulating Factor Market report are 300μg/Dose, 150μg/Dose, 75μg/Dose, Others

1 Human Granulocyte Colony-stimulating Factor Market Overview
1.1 Product Definition
1.2 Human Granulocyte Colony-stimulating Factor by Type
1.2.1 Global Human Granulocyte Colony-stimulating Factor Market Value Comparison by Type (2024 VS 2031)
1.2.2 300μg/Dose
1.2.3 150μg/Dose
1.2.4 75μg/Dose
1.2.5 Others
1.3 Human Granulocyte Colony-stimulating Factor by Application
1.3.1 Global Human Granulocyte Colony-stimulating Factor Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Human Granulocyte Colony-stimulating Factor Market Size Estimates and Forecasts
1.4.1 Global Human Granulocyte Colony-stimulating Factor Revenue 2020-2031
1.4.2 Global Human Granulocyte Colony-stimulating Factor Sales 2020-2031
1.4.3 Global Human Granulocyte Colony-stimulating Factor Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Human Granulocyte Colony-stimulating Factor Market Competition by Manufacturers
2.1 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Manufacturers (2020-2025)
2.2 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Human Granulocyte Colony-stimulating Factor Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Human Granulocyte Colony-stimulating Factor, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Product Type & Application
2.7 Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Date of Enter into This Industry
2.8 Global Human Granulocyte Colony-stimulating Factor Market Competitive Situation and Trends
2.8.1 Global Human Granulocyte Colony-stimulating Factor Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Human Granulocyte Colony-stimulating Factor Players Market Share by Revenue
2.8.3 Global Human Granulocyte Colony-stimulating Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Granulocyte Colony-stimulating Factor Market Scenario by Region
3.1 Global Human Granulocyte Colony-stimulating Factor Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Human Granulocyte Colony-stimulating Factor Sales by Region: 2020-2031
3.2.1 Global Human Granulocyte Colony-stimulating Factor Sales by Region: 2020-2025
3.2.2 Global Human Granulocyte Colony-stimulating Factor Sales by Region: 2026-2031
3.3 Global Human Granulocyte Colony-stimulating Factor Revenue by Region: 2020-2031
3.3.1 Global Human Granulocyte Colony-stimulating Factor Revenue by Region: 2020-2025
3.3.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Region: 2026-2031
3.4 North America Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.4.1 North America Human Granulocyte Colony-stimulating Factor Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Human Granulocyte Colony-stimulating Factor Sales by Country (2020-2031)
3.4.3 North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.5.1 Europe Human Granulocyte Colony-stimulating Factor Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2020-2031)
3.5.3 Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Region
3.6.1 Asia Pacific Human Granulocyte Colony-stimulating Factor Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2020-2031)
3.6.3 Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.7.1 Latin America Human Granulocyte Colony-stimulating Factor Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2020-2031)
3.7.3 Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Granulocyte Colony-stimulating Factor Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2020-2031)
3.8.3 Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Granulocyte Colony-stimulating Factor Sales by Type (2020-2031)
4.1.1 Global Human Granulocyte Colony-stimulating Factor Sales by Type (2020-2025)
4.1.2 Global Human Granulocyte Colony-stimulating Factor Sales by Type (2026-2031)
4.1.3 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2020-2031)
4.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2020-2031)
4.2.1 Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2020-2025)
4.2.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2026-2031)
4.2.3 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type (2020-2031)
4.3 Global Human Granulocyte Colony-stimulating Factor Price by Type (2020-2031)
5 Segment by Application
5.1 Global Human Granulocyte Colony-stimulating Factor Sales by Application (2020-2031)
5.1.1 Global Human Granulocyte Colony-stimulating Factor Sales by Application (2020-2025)
5.1.2 Global Human Granulocyte Colony-stimulating Factor Sales by Application (2026-2031)
5.1.3 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2020-2031)
5.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2020-2031)
5.2.1 Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2020-2025)
5.2.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2026-2031)
5.2.3 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application (2020-2031)
5.3 Global Human Granulocyte Colony-stimulating Factor Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Chugai Pharmaceutical
6.1.1 Chugai Pharmaceutical Company Information
6.1.2 Chugai Pharmaceutical Description and Business Overview
6.1.3 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.1.5 Chugai Pharmaceutical Recent Developments/Updates
6.2 Kyowa Hakko Kirin
6.2.1 Kyowa Hakko Kirin Company Information
6.2.2 Kyowa Hakko Kirin Description and Business Overview
6.2.3 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product Portfolio
6.2.5 Kyowa Hakko Kirin Recent Developments/Updates
6.3 Sanway
6.3.1 Sanway Company Information
6.3.2 Sanway Description and Business Overview
6.3.3 Sanway Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanway Human Granulocyte Colony-stimulating Factor Product Portfolio
6.3.5 Sanway Recent Developments/Updates
6.4 GenSci
6.4.1 GenSci Company Information
6.4.2 GenSci Description and Business Overview
6.4.3 GenSci Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GenSci Human Granulocyte Colony-stimulating Factor Product Portfolio
6.4.5 GenSci Recent Developments/Updates
6.5 SL PHARM
6.5.1 SL PHARM Company Information
6.5.2 SL PHARM Description and Business Overview
6.5.3 SL PHARM Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.5.4 SL PHARM Human Granulocyte Colony-stimulating Factor Product Portfolio
6.5.5 SL PHARM Recent Developments/Updates
6.6 Kexing Bioproducts
6.6.1 Kexing Bioproducts Company Information
6.6.2 Kexing Bioproducts Description and Business Overview
6.6.3 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product Portfolio
6.6.5 Kexing Bioproducts Recent Developments/Updates
6.7 Qilu Pharmaceutical
6.7.1 Qilu Pharmaceutical Company Information
6.7.2 Qilu Pharmaceutical Description and Business Overview
6.7.3 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.7.5 Qilu Pharmaceutical Recent Developments/Updates
6.8 CSPC
6.8.1 CSPC Company Information
6.8.2 CSPC Description and Business Overview
6.8.3 CSPC Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.8.4 CSPC Human Granulocyte Colony-stimulating Factor Product Portfolio
6.8.5 CSPC Recent Developments/Updates
6.9 Wuzhong Pharmaceutical
6.9.1 Wuzhong Pharmaceutical Company Information
6.9.2 Wuzhong Pharmaceutical Description and Business Overview
6.9.3 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.9.5 Wuzhong Pharmaceutical Recent Developments/Updates
6.10 Quangang Pharmaceutical
6.10.1 Quangang Pharmaceutical Company Information
6.10.2 Quangang Pharmaceutical Description and Business Overview
6.10.3 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.10.5 Quangang Pharmaceutical Recent Developments/Updates
6.11 Huabei Pharmaceutical
6.11.1 Huabei Pharmaceutical Company Information
6.11.2 Huabei Pharmaceutical Description and Business Overview
6.11.3 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.11.5 Huabei Pharmaceutical Recent Developments/Updates
6.12 Harbin Pharmaceutical
6.12.1 Harbin Pharmaceutical Company Information
6.12.2 Harbin Pharmaceutical Description and Business Overview
6.12.3 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.12.5 Harbin Pharmaceutical Recent Developments/Updates
6.13 Amoytop Biotech
6.13.1 Amoytop Biotech Company Information
6.13.2 Amoytop Biotech Description and Business Overview
6.13.3 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product Portfolio
6.13.5 Amoytop Biotech Recent Developments/Updates
6.14 Jiuyuan Gene Engineering
6.14.1 Jiuyuan Gene Engineering Company Information
6.14.2 Jiuyuan Gene Engineering Description and Business Overview
6.14.3 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product Portfolio
6.14.5 Jiuyuan Gene Engineering Recent Developments/Updates
6.15 Four Rings Biopharmaceutical
6.15.1 Four Rings Biopharmaceutical Company Information
6.15.2 Four Rings Biopharmaceutical Description and Business Overview
6.15.3 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.15.5 Four Rings Biopharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Granulocyte Colony-stimulating Factor Industry Chain Analysis
7.2 Human Granulocyte Colony-stimulating Factor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Granulocyte Colony-stimulating Factor Production Mode & Process Analysis
7.4 Human Granulocyte Colony-stimulating Factor Sales and Marketing
7.4.1 Human Granulocyte Colony-stimulating Factor Sales Channels
7.4.2 Human Granulocyte Colony-stimulating Factor Distributors
7.5 Human Granulocyte Colony-stimulating Factor Customer Analysis
8 Human Granulocyte Colony-stimulating Factor Market Dynamics
8.1 Human Granulocyte Colony-stimulating Factor Industry Trends
8.2 Human Granulocyte Colony-stimulating Factor Market Drivers
8.3 Human Granulocyte Colony-stimulating Factor Market Challenges
8.4 Human Granulocyte Colony-stimulating Factor Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Chugai Pharmaceutical
Kyowa Hakko Kirin
Sanway
GenSci
SL PHARM
Kexing Bioproducts
Qilu Pharmaceutical
CSPC
Wuzhong Pharmaceutical
Quangang Pharmaceutical
Huabei Pharmaceutical
Harbin Pharmaceutical
Amoytop Biotech
Jiuyuan Gene Engineering
Four Rings Biopharmaceutical
List of Tables
 Table 1. Global Human Granulocyte Colony-stimulating Factor Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Human Granulocyte Colony-stimulating Factor Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Human Granulocyte Colony-stimulating Factor Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) of Key Manufacturers (2020-2025)
 Table 5. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Human Granulocyte Colony-stimulating Factor Average Price (USD/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Human Granulocyte Colony-stimulating Factor, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Product Type & Application
 Table 12. Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Human Granulocyte Colony-stimulating Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Granulocyte Colony-stimulating Factor as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Granulocyte Colony-stimulating Factor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2020-2025) & (K Dose)
 Table 18. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2020-2025)
 Table 19. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2026-2031) & (K Dose)
 Table 20. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2026-2031)
 Table 21. Global Human Granulocyte Colony-stimulating Factor Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2020-2025)
 Table 23. Global Human Granulocyte Colony-stimulating Factor Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2026-2031)
 Table 25. North America Human Granulocyte Colony-stimulating Factor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2020-2025) & (K Dose)
 Table 27. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2026-2031) & (K Dose)
 Table 28. North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2020-2025) & (K Dose)
 Table 32. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2026-2031) & (K Dose)
 Table 33. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2020-2025) & (K Dose)
 Table 37. Asia Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2026-2031) & (K Dose)
 Table 38. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2020-2025) & (K Dose)
 Table 42. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2026-2031) & (K Dose)
 Table 43. Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2020-2025) & (K Dose)
 Table 47. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2026-2031) & (K Dose)
 Table 48. Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Type (2020-2025)
 Table 51. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Type (2026-2031)
 Table 52. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2020-2025)
 Table 53. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2026-2031)
 Table 54. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type (2020-2025)
 Table 57. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type (2026-2031)
 Table 58. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Type (2020-2025)
 Table 59. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Type (2026-2031)
 Table 60. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Application (2020-2025)
 Table 61. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Application (2026-2031)
 Table 62. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2020-2025)
 Table 63. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2026-2031)
 Table 64. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application (2020-2025)
 Table 67. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application (2026-2031)
 Table 68. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Application (2020-2025)
 Table 69. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Application (2026-2031)
 Table 70. Chugai Pharmaceutical Company Information
 Table 71. Chugai Pharmaceutical Description and Business Overview
 Table 72. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 73. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
 Table 74. Chugai Pharmaceutical Recent Developments/Updates
 Table 75. Kyowa Hakko Kirin Company Information
 Table 76. Kyowa Hakko Kirin Description and Business Overview
 Table 77. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 78. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product
 Table 79. Kyowa Hakko Kirin Recent Developments/Updates
 Table 80. Sanway Company Information
 Table 81. Sanway Description and Business Overview
 Table 82. Sanway Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 83. Sanway Human Granulocyte Colony-stimulating Factor Product
 Table 84. Sanway Recent Developments/Updates
 Table 85. GenSci Company Information
 Table 86. GenSci Description and Business Overview
 Table 87. GenSci Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 88. GenSci Human Granulocyte Colony-stimulating Factor Product
 Table 89. GenSci Recent Developments/Updates
 Table 90. SL PHARM Company Information
 Table 91. SL PHARM Description and Business Overview
 Table 92. SL PHARM Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 93. SL PHARM Human Granulocyte Colony-stimulating Factor Product
 Table 94. SL PHARM Recent Developments/Updates
 Table 95. Kexing Bioproducts Company Information
 Table 96. Kexing Bioproducts Description and Business Overview
 Table 97. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 98. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product
 Table 99. Kexing Bioproducts Recent Developments/Updates
 Table 100. Qilu Pharmaceutical Company Information
 Table 101. Qilu Pharmaceutical Description and Business Overview
 Table 102. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 103. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
 Table 104. Qilu Pharmaceutical Recent Developments/Updates
 Table 105. CSPC Company Information
 Table 106. CSPC Description and Business Overview
 Table 107. CSPC Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 108. CSPC Human Granulocyte Colony-stimulating Factor Product
 Table 109. CSPC Recent Developments/Updates
 Table 110. Wuzhong Pharmaceutical Company Information
 Table 111. Wuzhong Pharmaceutical Description and Business Overview
 Table 112. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 113. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
 Table 114. Wuzhong Pharmaceutical Recent Developments/Updates
 Table 115. Quangang Pharmaceutical Company Information
 Table 116. Quangang Pharmaceutical Description and Business Overview
 Table 117. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 118. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
 Table 119. Quangang Pharmaceutical Recent Developments/Updates
 Table 120. Huabei Pharmaceutical Company Information
 Table 121. Huabei Pharmaceutical Description and Business Overview
 Table 122. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 123. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
 Table 124. Huabei Pharmaceutical Recent Developments/Updates
 Table 125. Harbin Pharmaceutical Company Information
 Table 126. Harbin Pharmaceutical Description and Business Overview
 Table 127. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 128. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
 Table 129. Harbin Pharmaceutical Recent Developments/Updates
 Table 130. Amoytop Biotech Company Information
 Table 131. Amoytop Biotech Description and Business Overview
 Table 132. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 133. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product
 Table 134. Amoytop Biotech Recent Developments/Updates
 Table 135. Jiuyuan Gene Engineering Company Information
 Table 136. Jiuyuan Gene Engineering Description and Business Overview
 Table 137. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 138. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product
 Table 139. Jiuyuan Gene Engineering Recent Developments/Updates
 Table 140. Four Rings Biopharmaceutical Company Information
 Table 141. Four Rings Biopharmaceutical Description and Business Overview
 Table 142. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 143. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product
 Table 144. Four Rings Biopharmaceutical Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Human Granulocyte Colony-stimulating Factor Distributors List
 Table 148. Human Granulocyte Colony-stimulating Factor Customers List
 Table 149. Human Granulocyte Colony-stimulating Factor Market Trends
 Table 150. Human Granulocyte Colony-stimulating Factor Market Drivers
 Table 151. Human Granulocyte Colony-stimulating Factor Market Challenges
 Table 152. Human Granulocyte Colony-stimulating Factor Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Granulocyte Colony-stimulating Factor
 Figure 2. Global Human Granulocyte Colony-stimulating Factor Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Human Granulocyte Colony-stimulating Factor Market Share by Type: 2024 & 2031
 Figure 4. 300μg/Dose Product Picture
 Figure 5. 150μg/Dose Product Picture
 Figure 6. 75μg/Dose Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Human Granulocyte Colony-stimulating Factor Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Human Granulocyte Colony-stimulating Factor Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Global Human Granulocyte Colony-stimulating Factor Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Human Granulocyte Colony-stimulating Factor Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Human Granulocyte Colony-stimulating Factor Sales (2020-2031) & (K Dose)
 Figure 15. Global Human Granulocyte Colony-stimulating Factor Average Price (USD/Dose) & (2020-2031)
 Figure 16. Human Granulocyte Colony-stimulating Factor Report Years Considered
 Figure 17. Human Granulocyte Colony-stimulating Factor Sales Share by Manufacturers in 2024
 Figure 18. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Human Granulocyte Colony-stimulating Factor Players: Market Share by Revenue in Human Granulocyte Colony-stimulating Factor in 2024
 Figure 20. Human Granulocyte Colony-stimulating Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Human Granulocyte Colony-stimulating Factor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2020-2031)
 Figure 23. North America Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2020-2031)
 Figure 27. Europe Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2020-2031)
 Figure 35. China Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. UAE Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Human Granulocyte Colony-stimulating Factor by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Human Granulocyte Colony-stimulating Factor by Type (2020-2031)
 Figure 57. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Human Granulocyte Colony-stimulating Factor by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Human Granulocyte Colony-stimulating Factor by Application (2020-2031)
 Figure 60. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Application (2020-2031)
 Figure 61. Human Granulocyte Colony-stimulating Factor Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions